Thought LeaderMina MakarSenior Vice President, Global CVRMAstraZeneca
NewsMedical spoke with Mina Makar, Senior Vice President of Global CVRM at AstraZeneca, about groundbreaking research in Heart Failure and Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM). Mina shares insights on AstraZeneca’s mission to address unmet needs in cardiovascular care and the future of personalized medicine.
Firstly, please introduce yourself and tell us about your career to date
I hold the role of Senior Vice President, Global Cardiovascular, Renal and Metabolism (CVRM) in the BioPharmaceuticals Business Unit at AstraZeneca. In this role, I address the unmet needs in four inter-related disease areas: metabolism, heart failure, cardiovascular disease, and renal diseases, helping to drive our ambition to stop, reverse, and cure these chronic, progressive, and often devastating diseases by maximizing our medicines, delivering innovative solutions and advancing our pipeline.
I began my 30-year career in healthcare as a pharmacist and have since helped to bring important medicines to people who have very few or limited options. I’ve joined the CVRM team with deep experience in marketing and sales, payer and access strategies, and leadership and engagement. Recognizing the deep commitment we have in this important therapy area, I look forward to leading AstraZeneca into the future of CVRM care for the millions of people globally living with these conditions.
I’m so proud of the work we are doing to address existing unmet medical needs and set the future of CVRM care. Our collective success is what happens when our work reflects our passion.
Image Credit: sasirin pamai/Shutterstock.com
Click here